CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.

Zöphel S, Küchler N, Jansky J, Hoxha C, Schäfer G, Weise JJ, Vialle J, Kaschek L, Stopper G, Eichler H, Yildiz D, Moter A, Wendel P, Ullrich E, Schormann C, Rixecker T, Cetin O, Neumann F, Orth P, Bewarder M, Hoth M, Thurner L, Schwarz EC

Open source

DOI: 10.1186/s12943-024-02123-7
Published: 2024 Sep 28
Container: Molecular cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12943-024-02123-7,
  title = {CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.},
  author = {Zöphel S and Küchler N and Jansky J and Hoxha C and Schäfer G and Weise JJ and Vialle J and Kaschek L and Stopper G and Eichler H and Yildiz D and Moter A and Wendel P and Ullrich E and Schormann C and Rixecker T and Cetin O and Neumann F and Orth P and Bewarder M and Hoth M and Thurner L and Schwarz EC},
  year = {2024},
  journal = {Molecular cancer},
  doi = {10.1186/s12943-024-02123-7},
  url = {https://doi.org/10.1186/s12943-024-02123-7}
}

RIS

TY  - JOUR
TI  - CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.
AU  - Zöphel S
AU  - Küchler N
AU  - Jansky J
AU  - Hoxha C
AU  - Schäfer G
AU  - Weise JJ
AU  - Vialle J
AU  - Kaschek L
AU  - Stopper G
AU  - Eichler H
AU  - Yildiz D
AU  - Moter A
AU  - Wendel P
AU  - Ullrich E
AU  - Schormann C
AU  - Rixecker T
AU  - Cetin O
AU  - Neumann F
AU  - Orth P
AU  - Bewarder M
AU  - Hoth M
AU  - Thurner L
AU  - Schwarz EC
PY  - 2024
JO  - Molecular cancer
DO  - 10.1186/s12943-024-02123-7
UR  - https://doi.org/10.1186/s12943-024-02123-7
ER  -

APA

S, Z., N, K., J, J., C, H., G, S., JJ, W., J, V., L, K., G, S., H, E., D, Y., A, M., P, W., E, U., C, S., T, R., O, C., F, N., P, O., M, B., M, H., L, T., & EC, S. (2024). CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.. Molecular cancer. https://doi.org/10.1186/s12943-024-02123-7

Source records

pubmed · retrieved 2026-09-25T23:55:37.510Z